PD-1

Anti-Mouse PD-1 Antibody (RMP1-14) is an IgG2a antibody inhibitor against mouse PD-1 and can block PD-1/PD-L1 signaling.

PD-1/PD-L1-IN-20 is a small molecule inhibitor of PD-1/PD-L1 protein-protein interaction, blocking the interaction with an IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used to study cancer, infectious diseases, and autoimmune diseases.

Anti-PDCD1/PD-1/CD279 Antibody is a human-derived antibody expressed in CHO cells, specifically targeting PDCD1/PD-1/CD279. This antibody features a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control, refer to [HumanIgG4kappa, Isotype Control].

Anti-Mouse PD-1 Antibody (J43) is an inhibitory antibody derived from Armenian hamsters, with its target being mouse PD-1. This antibody can effectively block the interaction between PD-1 and PD-L1, and is widely used in cancer and immunology-related research, including research directions such as breast cancer and colon cancer.

Anti-Mouse PD-1 Antibody (29F.1A12), a rat-derived ntibody targeting PD-1, can specifically block the binding of PD-1 to its ligands PD-L1 and PD-L2. Based on this mechanism of action, it is widely applicable to research in cancer and immunology, including studies on the CT26 tumor model and pancreatic cancer research. Its isotype control is Rat IgG2a kappa Isotype Control.

Anti-Human/Mouse/Monkey PD-1 Antibody (2E5) is a monoclonal antibody targeting human, mouse and monkey PD-1 and can be used in cancer immunotherapy research.

Anti-Human PD-1/CD279 Antibody (J116)（Programmed Death-1）is a monoclonal antibody targeting human PD‑1 and can be used in cancer immunotherapy research.

Anti-Human PD-1/CD279 Antibody (J110) targets the extracellular domain of PD-1 (CD279), and specifically recognizes the native PD-1 receptor on the surface of activated T cells, B cells and myeloid cells.

Anti-Mouse PD-1/CD279 (D265A) Antibody (29F.1A12) is a rat-derived inhibitory antibody that targets mouse PD-1 and blocks its binding to both PD-L1 and PD-L2 ligands.It is suitable for cancer and immunology research, including CT26 tumors and pancreatic cancer models .

Anti-MousePD-1Antibody (S-5001) is an IgG1 antibody inhibitor that targets mouse PD-1.

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived antibody specifically used to inhibit phosphorylated PD-1/CD279 in mice or humans. It can detect the phosphorylated form of the PD-1 immunoreceptor tyrosine-based inhibitory motif by Western blotting and flow cytometry .

Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.

Anti-MousePD-1Antibody (D265A) is an antibody inhibitor targeting the PD-1 protein in mice.

Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.

Nivolumab is a monoclonal antibody and is a humanized PD-1 antibody. Nivolumab has anti-tumor activity and is used in the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, etc.

Pembrolizumab (MK-3475) is a highly selective humanized monoclonal antibody that antagonizes PD-1. It can block the PD-1 protein on T cells and prevent their interaction with PD-L1 on cancer cells.

Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer.

Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity directed against PD-1, binding PD-1 with an affinity of up to 3 nM and inhibiting PD-1/PD-L1 with an IC50 of 0.70 nM. Camrelizumab exhibits anti-tumor activity and is well tolerated in cancers, including NSC-LC, ESCC, Hodgkin's lymphoma, and advanced HCC.

Tislelizumab (BGB-A317) is an IgG4 class monoclonal antibody targeting human programmed death receptor-1 (PD-1) with antitumor activity that inhibits the binding of Fcγ receptor to macrophages and can be used to study advanced squamous non-small cell lung cancer.

Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors.

Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.Latikafusp initiates and prolongs cytotoxicity and memory T-cell activity and induces the generation of immunogenicity-mediated responses.